AUGMENTATION OF IN VITRO HUMORAL IMMUNE RESPONSES IN THE MOUSE BY AN ANTIBODY TO IgD*

By FRED D. FINKELMAN, VIRGIL L. WOODS, SHANNON B. WILBURN, JAMES J. MOND, KATHRYN E. STEIN, ALICE BERNING, AND IRWIN SCHER

From the Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Md. 20014; the Laboratory of Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md. 20205; and the Department of Immunology, Naval Medical Research Institute, Bethesda, Maryland 20014

The identification of IgD in normal human serum (1) and its subsequent discovery of on the surface of most primate (2-5) and rodent (6-9) B lymphocytes generated questions regarding the function of this Ig isotype. In studying this problem, Pernis (10) injected rhesus monkeys with a rabbit antiserum specific for human IgD (RaHδ),1 which cross-reacts with monkey IgD. These monkeys developed substantial increases in serum IgM and IgG levels, which were entirely accounted for by antibodies specific for constituents of rabbit serum. These experiments suggested that anti-IgD can have an adjuvant effect on the humoral immune response to simultaneously injected foreign antigens (10), but is not a polyclonal activator of B lymphocyte terminal differentiation. Pernis's interpretation has been supported by other studies that demonstrated that the injection of an IgG fraction of RaHδ or affinity-purified RaHδ into rhesus monkeys could considerably enhance the IgG response to a subsequently injected antigen, but did not lead to a polyclonal increase in serum IgM or IgG levels (11, 12).

The adaptation of this model to the mouse has been made possible by the production of hybridoma-derived monoclonal anti-mouse δ-chain antibodies (13). One such antibody is an IgG2a of the b allotype secreted by hybridoma 10-4.22 (14) that has specificity for the Fc fragment of mouse δ-chain of the a allotype (4.22aM8α) (15). We report here the effects of 4.22aM8α on the IgM and IgG anti-2,4,6-trinitro-

---

* Supported by the Uniformed Services University of the Health Sciences: Research R08307, R08308, and C08410; and the Naval Medical Research and Development Command: Work Unit M0095-PN.001.1030.

† Supported by U. S. Public Health Service National Research Service Award 7F32CA05328-02.

Abbreviations used in this paper: AECM, aminoethylcarbamylmethylated; 4.22aM8α, IgG2a antibody of the b allotype secreted by hybridoma 10-4.22 that has specificity for the Fc fragment of mouse δ-chain of the a allotype; FACS, fluorescence-activated cell sorter; FITC, fluorescein isothiocyanate; HFA, Hanks' balanced salt solution supplemented with 10% fetal bovine serum and 0.2% NaN3; NIH, National Institutes of Health; OVA, ovalbumin; RaHδ, rabbit antiserum specific for human IgD; Ra4.Z2Id, rabbit antibody against the idiotypic determinants of 4.22aM8α, RaKLH, rabbit anti-keyhole limpet hemocyanin; RaMδ, rabbit anti-mouse δ-chain; RaMy, rabbit anti-mouse γ-chain; RaMP, rabbit anti-mouse μ-chain; sIgD, surface IgD; sIgM, surface IgM; SRBC, sheep erythrocytes; TNP, 2,4,6-trinitrophenyl; TNP-Ficol, TNP-AECM-Ficol; TNP-SRBC 2,4,6-trinitrophenylated SRBC.
phenyl (TNP) response to TNP-conjugated sheep erythrocytes (SRBC) (TNP-SRBC) and TNP-conjugated aminoethylcarbamylmethylated (AECM)-Ficoll (TNP-Ficoll).

Our results indicate that although 4.22aM8 by itself stimulates neither B cell proliferation nor terminal differentiation when injected into BALB/c mice, it substantially enhances the IgG anti-TNP response and modestly enhances the IgM anti-TNP response to subsequently injected TNP-Ficoll or TNP-SRBC. We have found that the degree of enhancement of the IgG anti-TNP response is highly dependent on the dose of TNP-SRBC or TNP-Ficoll used and on the time interval between injection of 4.22aM8 and antigen, and that even in the case of the T-independent antigen TNP-Ficoll this enhancement appears to be T lymphocyte dependent.

Materials and Methods

**Animals.** Male BALB/c mice were obtained from Microbiological Associates, Walkersville, Md. Male athymic (nu/nu) mice and their phenotypically normal (+/+ and nu/+) littermates were obtained from the Small Animal Section, Division of Research Services, National Institutes of Health (NIH), Bethesda, Md. Male C.B20 mice, which are congenic to BALB/c but possess the IgH genes of C57BL/Ka, were bred from mice originally obtained from Dr. Michael Potter, NIH. All mice were at least 8 wk old when used.

**Antigens.** TNP-Ficoll Ficoll was purchased from Biosearch, St. Raphael, Calif. TNP-SRBC with a high hapten density were prepared as previously described (16).

**Antibodies.** The preparation of the following antibodies has been described elsewhere: isotype-specific affinity purified rabbit anti-mouse γ-chain (RaMy) and rabbit anti-mouse μ-chain (RaMu) (17), affinity-purified rabbit anti-keyhole limpet hemocyanin (RaKLH), and 4.22aM8 (18). The monoclonal IgG2a secreted by the plasmacytoma CBPC-101, which does not bind to mouse cells, was purified from the ascites fluid of C.B20 mice that bore this tumor by elution from protein A-Sepharose. Both 4.22aM8 and CBPC-101 bear the b allotypic determinants characteristics of C57BL/6 IgG2a immunoglobulins. A rabbit antibody against idiotypic determinants of 4.22aM8 (Ra4.22Id) was prepared by immunizing a rabbit with 4.22aM8, absorbing the antiserum with normal BALB/c serum-Sepharose, and immunospecifically purifying the absorbed antiserum on a column of 4.22aM8-Sepharose. The identification and purification of two mouse IgDx plasmacytoma proteins, TEPC-1017 and TEPC-1033, and the production of an affinity-purified isotype-specific rabbit anti-mouse δ-chain (RaMδ) antibody will be described in detail in a separate paper (F. Finkelman, S. Kessler, F. Mushinski, and M. Potter. Manuscript in preparation.). RaMu and RaMy were labeled with Na[125I] (Amersham Corp., Arlington Heights, Ill.) by the chloramine T technique (19); and 4.22aM8 and F(ab')2 fragments of affinity-purified RaMδ, RaMu, RaMy, and RaKLH were labeled with fluorescein isothiocyanate (FITC) to molar fluorescein:protein ratios of from 2:1 to 5:1 as previously described (20).

**Measurement of Serum Immunoglobulin Levels.** Serum IgG and IgM were quantitated by the radial immunodiffusion technique. IgG1, IgG2a, and IgG2b levels in 10-μl serum samples were measured with radial immunodiffusion plates purchased from Meloy Laboratories Inc., (Springfield, Va.). In other experiments, radial immunodiffusion plates prepared with RaMy that was sequentially affinity purified on columns of mouse IgG1 and IgG2a plasmacytoma proteins that were bound to Sepharose were used to measure total IgG levels. Serum IgM levels were measured with radial immunodiffusion plates prepared with isotype-specific RaMu antiserum.

**Quantitation of Immunoglobulin on Mouse Spleen Cells.** Single cell suspensions were prepared from spleens of BALB/c mice that had been injected with 200 μg of CBPC-101 or 4.22aM8, treated with erythrocyte lysing buffer, and suspended in Hanks' balanced salt solution that contained 10% fetal bovine serum and 0.2% NaNO3 (HFA). Aliquots of 2 × 10⁷ spleen cells in 100 μl of HFA were stained for 30 min at 0°C with 0.5 μg of FITC-labeled CBPC-101, 4.22aM8, or affinity-purified F(ab')2 fragments of RaMδ, RaMu, RaMy, or RaKLH; washed; and analyzed for surface fluorescence with a fluorescence-activated cell sorter (FACS II; Becton, Dickinson FACS Systems, Mountain View, Calif.) as previously described (20, 21).

**Measurement of Spleen Cell Proliferation.** Spleen cell suspensions were prepared from mice
injected with 4.22aMδ or CBPC-101. Triplicate cultures of 5 × 10⁶ cells each were incubated in flat-bottomed wells of microtiter plates in 0.2 ml of modified Mishell-Dutton medium with 1 μCi of [³H]thymidine/well for 4 or 24 h. Cells were harvested with a Mash II harvester (Microbiological Associates) and [³H]thymidine incorporation was analyzed by scintillation spectroscopy.

**Titration of Anti-TNP Levels in Mouse Sera.** IgG and IgM anti-TNP antibody levels in mice immunized with TNP-SRBC or TNP-Ficoll were titered with a solid-phase microtiter plate radioimmunoassay (22). TNP-Ficoll coated U-bottomed Wells in Flexvinyl microtiter plates (Cooke Engineering Co., Alexandria, Va.) were washed with 0.1% ovalbumin (OVA) in Tris. Negative control plates were prepared without TNP-Ficoll. Positive control plates were prepared by exposing wells to 100 μg/ml of IgG1, IgG2a, IgG3, or IgM instead of TNP-Ficoll. Individual sera were diluted to 1:40, 1:160, 1:640, and 1:2,560 in OVA-Tris buffer. Duplicate 25-μl aliquots of each serum dilution were pipetted into TNP-Ficoll-coated wells and incubated for 30 min at room temperature, after which, wells were washed, refilled with 25 μl of ¹²⁵I-RaMδ or ¹²⁵I-RaMδ (10⁸ cpm/ml) in OVA-Tris buffer, incubated for 1 h at room temperature, and washed again. Individual wells were cut from plates and counted in a gamma counter. In preliminary experiments, ~8 × 10⁶ cpm of ¹²⁵I-RaMδ bound to IgM-coated wells, and ~6 × 10⁶, ~4 × 10⁵, and ~1.5 × 10⁴ cpm of ¹²⁵I-RaMδ bound to IgG1-, IgG2a-, and IgG3-coated wells, respectively. Less than 10³ cpm of either reagent bound to wells coated either with OVA only or with TNP-Ficoll and OVA but which were not exposed to mouse serum. Less than 10³ cpm of ¹²⁵I-RaMδ bound to mouse IgG-coated wells and, similarly, <10³ cpm of ¹²⁵I-RaMδ bound to mouse IgM-coated wells. In general, TNP-Ficoll-coated wells exposed to an immune mouse serum bound 5-10 times as much ¹²⁵I-RaMδ and 10-20 times as much ¹²⁵I-RaMδ as OVA-coated wells exposed to the same dilution of the same serum. Serum titers were defined as the reciprocal of the serum dilution which was calculated by linear regression analysis of logarithms of serum dilutions to bind a given number of cpm of ¹²⁵I-RaMδ or ¹²⁵I-RaMδ (titration point). Titer points were chosen to allow for titration of all serum samples analyzed without extrapolation, and, when possible, to intersect titration curves of individual sera plotted on log-log paper at the steepest part of their slopes. Serum titers obtained this way provide only for relative measurement of serum antibody levels of simultaneously analyzed sera.

**Results**

**Effects on Cell Surface Immunoglobulin.** 1, 3, 5, or 7 d after 10-wk-old BALB/c mice were injected intravenously with 200 μg of 4.22aMδ or CBPC-101, their spleen cells were obtained and stained with FITC-labeled RaMδ, RaKLH, 4.22aMδ, CBPC-101, RaMµ, or RaMγ. Fig. 1 shows the fluorescence profiles obtained by FACS II analysis of cells taken 3 and 7 d after in vivo injection of 4.22aMδ or CBPC-101 and stained with FITC-labeled RaMδ, RaKLH, or RaMµ. 3 d after the 4.22aMδ injection, the intensity of spleen cell staining for surface IgD (sIgD) is greatly diminished and approaches the low value of cells stained nonspecifically with FITC-RaKLH. Similar profiles were obtained from cells derived from mice given 4.22aMδ 24 h previously that were stained with either FITC-RaMδ or FITC-4.22aMδ. Cells from mice injected with 4.22aMδ stained no more brightly with FITC-RaMγ, which binds to 4.22aMδ, than did cells from CBPC-101-injected mice (data not shown). Thus, decreased FITC-RaMδ staining of cells from 4.22aMδ-treated mice is a result of modulation of sIgD rather than blocking of β-chain determinants by 4.22aMδ. Spleen cells from mice injected 5 or 7 d previously with 4.22aMδ had considerably more sIgD than did cells from spleens removed 1 or 3 d after the 4.22aMδ injection, but considerably less than did spleen cells from control mice. Fig. 1 also shows that 3 and 7 d after in vivo 4.22aMδ treatment, the frequency of spleen cells that bore detectable surface IgM (sIgM) was diminished: 28-29% as compared to 44% in mice that had received CBPC-101. Because the total number of cells that bore cell surface I-region
Two groups of six BALB/c mice were injected with 200 µg of CBPC-101 (---) or 4.22αMδa (- - -)/mouse. Three mice from each group were killed 3 d later and their spleen cells were pooled and stained with FITC-RαMδ (A) or FITC-RαMµ (B). These cells were then analyzed for fluorescence intensity with a FACS. To provide a measure of nonspecific staining, spleen cells from CBPC-101-treated mice were stained with FITC-RαKLH (-----) and similarly analyzed. In the fluorescence profiles shown, the fluorescence intensity of stained cells increases along the abscissa, while the ordinate depicts the number of cells at each level of fluorescence intensity. (C) and (D) show fluorescence profiles of spleen cells obtained from mice injected with 4.22αMδa or CBPC-101 7 d before killing and stained with FITC-RαMδ (C) or FITC-RαMµ (D) as well as with FITC-RαKLH.

-associated (Ia) antigen or a receptor for the third component of complement was not diminished by this treatment, (data not shown) this result suggests that some B cells lose slgM as well as slgD after treatment with 4.22αMδa.

**Persistence of Injected 4.22αMδa.** Sera from six mice injected with 200 or 800 µg of 4.22αMδa were obtained 5 and 7 d after the 4.22αMδa injection and were analyzed for their ability to form a precipitin line with Ra4.22Id (100 µg/ml) in Ouchterlony plates. Sera from all six mice injected 5 d or 7 d previously with 800 µg of 4.22αMδa, sera from all six mice injected 5 d previously with 200 µg of 4.22αMδa, and three of six sera from mice injected 7 d previously with 200 µg of 4.22αMδa generated precipitin lines with Ra4.22Id antibody.

**Effects of In Vivo 4.22αMδa on the Humoral Immune Response to TNP-Ficoll and TNP-SRBC.** BALB/c mice were injected intravenously with 100 µg of 4.22αMδa or CBPC-101 and were given 0.2 ml of 10% TNP-SRBC intravenously or 100 µg of TNP-Ficoll intraperitoneally 24 h later. Serum samples obtained before and 5, 7, 10, and 13 d after immunization were assayed for their IgG and IgM anti-TNP titers by radioimmunoassay. Fig. 2 shows log-log plots of counts per minute of 125I-RαMµ bound to serial fourfold dilutions of sera obtained 5 d after TNP-SRBC immunization and similar plots of counts per minute of 125I-RαMγ bound to dilutions of sera drawn 7 d postimmunization. Each point represents the geometric mean of the counts per minute
Fig. 2. Effect of 4.22aMβ on the anti-TNP response in TNP-SRBC-immunized mice. Two groups of six BALB/c mice were given 100 μg of 4.22aMβ (○) or CBPC-101 (△)/mouse 1 d before injection with 0.2 ml of 10% TNP-SRBC. Sera obtained 5 d after immunization were assayed for IgM anti-TNP antibody (A), whereas sera obtained 7 d after immunization were assayed for IgG anti-TNP antibody (B). 40-, 160, 640-, and 2,560-fold dilutions of individual sera were analyzed by solid-phase microtiter plate radioimmunoassay for the counts per minute of 125I-labeled RaMß or RaMy that were bound to mouse antibody that was adherent to TNP-Ficoll-coated wells. Each point represents the geometric mean × SE of counts per minute of 125I-antibody bound by the specified dilution of sera from six mice.

TABLE I

Effects of 4.22aMβ, CBPC-101, or No Antibody on the Primary Anti-TNP Response to TNP-SRBC in BALB/c Mice

| Antibody injected | IgM (day 5) | IgG (day 7) |
|-------------------|-------------|-------------|
| None              | 130 (1.51)  | 133 (1.20)  |
| CBPC-101          | 328 (1.11)  | 171 (1.26)  |
| 4.22aMβ           | 679 (1.20)  | 1,560 (1.23) |

Three groups of six BALB/c mice were given no antibody, 200 μg of CBPC-101, or 200 μg of 4.22aMβ/mouse, followed by immunization with 0.2 ml of 10% TNP-SRBC 1 d later.

* Geometric mean. Standard error in parentheses.

of 125I-RaMß or RaMy bound by a given dilution of serum from 6 mice. Sera from mice that received 4.22aMβ had approximately five times as much IgG anti-TNP antibody and approximately twice as much IgM anti-TNP antibody as mice that received CBPC-101. It should be noted that similar relative differences in titer between sera from 4.22aMβ- and CBPC-101-treated mice would be calculated if the IgG anti-TNP titer point were chosen anywhere between 4 × 10³ and 4.5 × 10⁴ cpm and if the IgM anti-TNP titer point were chosen anywhere between 4 × 10⁸ and 3 × 10⁹ cpmp.

To assure that the enhancement seen in 4.22aMβ-treated mice did not actually reflect suppression by the control immunoglobulin, CBPC-101, three groups of six mice each were injected with 200 μg of CBPC-101, 200 μg of 4.22aMβ, or no antibody, followed by immunization 24 h later with TNP-SRBC. As shown in Table I, 5-d postimmunization sera from mice given 4.22aMβ had a geometric mean IgM
Table II

Effects of 4.22aM8 on Primary Anti-TNP Response to TNP-SRBC in C. B20 Mice

| Antibody injected | Serum titer* |
|-------------------|--------------|
|                   | IgM (day 5)  | IgG (day 7) |
| 4.22aM8           | 175 (1.29)   | 374 (1.43)  |
| CBPC-101          | 149 (1.23)   | 399 (1.28)  |

Two groups of six C.B20 mice were given 200 μg of 4.22aM8 or CBPC-101/mouse, followed by immunization with 0.2 ml of 10% TNP-SRBC 1 d later.

* Geometric mean. Standard error in parentheses.

anti-TNP titer approximately twice that of mice given CBPC-101 and approximately five times that of mice given no antibody; whereas sera obtained from 4.22aM8-treated mice 7 d after immunization contained approximately ninefold more IgG anti-TNP antibody than mice given CBPC-101 or no antibody. In another experiment, the ability of 4.22aM8 to enhance anti-TNP antibody production by C.B20 mice immunized with TNP-SRBC was analyzed. Because 4.22aM8 binds IgD of the a allotype (found in BALB/c mice) but not of the b allotype (found in C57BL/Ka mice) and C.B20 mice are a BALB/c congenic strain that has C57BL/Ka Ig heavy-chain genes, 4.22aM8 would be expected to enhance anti-TNP antibody production in these mice if the enhancing factor were something other than anti-δ-chain activity. C.B20 mice treated with 4.22aM8 made no more IgM or IgG anti-TNP antibody than did mice treated with CBPC-101 (Table II).

We next studied the kinetics of anti-δ-chain enhancement of anti-TNP antibody responses in mice immunized with TNP-Ficoll or TNP-SRBC 24 h after injection with 4.22aM8 or CBPC-101. These experiments demonstrated that IgM anti-TNP titers were higher on day 5 than on day 7, whereas IgG titers were higher on day 7 than on days 5, 10, or 13 (data not shown). At all times studied, IgG anti-TNP titers in the mice that received 4.22aM8 exceeded those of CBPC-101 recipients by a factor of approximately five, whereas the enhancement of IgM anti-TNP antibody production by 4.22aM8 was approximately twofold.

We next examined the effects of varying the doses of antigen and 4.22aM8 on anti-δ-chain enhancement of anti-TNP antibody responses. Mice were injected with 25, 100, or 800 μg of 4.22aM8 or CBPC-101 24 h before TNP-SRBC immunization. 5- and 7-d sera were titrated for IgM and IgG anti-TNP antibody, respectively. Both IgG and IgM titers were higher in sera obtained from mice that had received 4.22aM8 instead of CBPC-101 at all three antibody doses tested (data not shown), and the variation observed with different antibody doses was not substantial. Enhancement of the IgG anti-TNP response by 4.22aM8 does appear, however, to be highly dependent upon the dose of antigen administered. As is seen in Fig. 3A, the IgG anti-TNP response decreased with decreasing amounts of TNP-SRBC and this effect was particularly pronounced in mice that had received 4.22aM8 rather than CBPC-101. Mice given 4.22aM8 before immunization with 0.2 ml of 10, 1, or 0.1% TNP-SRBC made 9.2-, 2.5-, and 1.1-fold more IgG anti-TNP antibody, respectively, than did mice immunized with the same quantity of antigen after having received CBPC-101. Similarly, the IgG anti-TNP response to 100 μg of TNP-Ficoll was enhanced more by 4.22aM8 (9.4-fold) than the response to 10 μg or 1 μg of TNP-
FIG. 3. Effect of antigen dose on 4.22aM8\textsuperscript{a} enhancement of the anti-TNP humoral immune response. Two groups of 36 BALB/c mice were given 200 \mu g of 4.22aM8\textsuperscript{a} (\textendash\textendash\textendash) or CBPC-101 (\textendash\textendash\textendash\textendash) per mouse. 1 d later, six mice in each group were immunized with 1, 10, or 100 \mu g of TNP-Ficoll (\Delta) or 0.2 ml of 0.1, 1, or 10\% TNP-SRBC (O)/mouse. Sera obtained 5 and 7 d after immunization were titered for IgM anti-TNP levels (A) and IgG anti-TNP levels (B), respectively. Each point represents the geometric mean \times SE of the titers of six individual sera.

Ficoll (5.8-fold or 1.9-fold, respectively). Although a similar trend was seen in 4.22aM8\textsuperscript{a} enhancement of the IgM anti-TNP response (Fig. 3B) the effects of variation of antigen dose on enhancement of IgM anti-TNP was much less striking than that seen on IgG anti-TNP levels. The lack of any enhancement by 4.22aM8\textsuperscript{a} of either the IgG or IgM anti-TNP response of 0.2\% TNP-SRBC is particularly meaningful, as it indicates that 4.22aM8\textsuperscript{a} in the absence of other antigens does not induce any detectable anti-TNP humoral immune response (i.e., it is not a polyclonal activator).

The effect of varying the interval between administration of 4.22aM8\textsuperscript{a} or CBPC-101 and antigen was studied in experiments in which sera were obtained 5 and 7 d after TNP-SRBC administration for determination of IgM and IgG anti-TNP titers, respectively. Administration of 4.22aM8\textsuperscript{a} 1 d before antigen enhanced the IgG anti-TNP response more than when 4.22aM8\textsuperscript{a} was given simultaneously with or 3 d before antigen (Fig. 4). Furthermore, no significant 4.22aM8\textsuperscript{a} enhancement was seen when 4.22aM8\textsuperscript{a} was given 7 or 14 d before antigen or 3 d after antigen. The effect of varying the interval between 4.22aM8\textsuperscript{a} and TNP-SRBC administration on the IgM anti-TNP response was less striking.

The possibility that T lymphocytes might play a role in 4.22aM8\textsuperscript{a} enhancement of humoral immune responses was studied by giving 200 \mu g of 4.22aM8\textsuperscript{a} or CBPC-101
Fig. 4. Effect of varying the interval between administration of 4.22aM8* and TNP-SRBC or 4.22aM8* enhancement of the humoral anti-TNP response. Groups of six BALB/c mice were given 200 μg of CBPC-101 (---) or 4.22aM8* (- - -) mouse 1, 2, 3, or 4 days before immunization with 0.2 ml of 10% TNP-SRBC or were given CBPC-101 or 4.22aM8* simultaneously with, or 3 days after, TNP-SRBC immunization. IgM and IgG anti-TNP titers were obtained for sera drawn 5 days (A) and 7 days (B) after immunization, respectively.

| TABLE III |

Effect of 4.22aM8* on nu/nu and Normal Anti-TNP Responses to TNP-SRBC and TNP-Ficoll

| Experiment | Mice       | Antibody     | IgM TNP-SRBC | IgM TNP-Ficoll | IgG TNP-SRBC | IgG TNP-Ficoll |
|------------|------------|--------------|--------------|----------------|--------------|----------------|
| 1          | Normal‡    | 4.22aM8*     | 538 (1.26)   | 499 (1.62)     | 949 (1.62)   | 1,510 (1.35)   |
|            | CBPC-101   | 355 (1.43)   | 259 (1.32)   | 144 (1.55)     | 275 (1.59)   |                |
|            | nu/nu      | 4.22aM8*     | 0            | 466 (1.19)     | 0            | 489 (1.33)     |
|            | CBPC-101   | 0            | 636 (1.27)   | 0              | 407 (1.64)   |                |
| 2          | nu/nu      | 4.22aM8*     |              |                | 209 (1.29)   |                |
|            | CBPC-101   |              |              |                | 207 (1.10)   |                |

In experiment 1, groups of six athymic (nu/nu) mice or their phenotypically normal littermates were given 200 μg of CBPC-101 or 4.22aM8*/mouse 1 day before immunization with 100 μg of TNP-Ficoll or 0.2 ml of 10% TNP-SRBC. Sera obtained 5 and 7 days after immunization were titered for IgM and IgG anti-TNP antibody levels, respectively. Experiment 2 is a partial repeat of experiment 1, with only athymic mice and TNP-Ficoll.

* Geometric mean. Standard error in parentheses.
‡ nu/+ or +/+ littermates of nu/nu mice.

TABLE III

Effect of 4.22aM8* on nu/nu and Normal Anti-TNP Responses to TNP-SRBC and TNP-Ficoll

In experiment 1, groups of six athymic (nu/nu) mice or their phenotypically normal littermates were given 200 μg of CBPC-101 or 4.22aM8*/mouse 1 day before immunization with 100 μg of TNP-Ficoll or 0.2 ml of 10% TNP-SRBC. Sera obtained 5 and 7 days after immunization were titered for IgM and IgG anti-TNP antibody levels, respectively. Experiment 2 is a partial repeat of experiment 1, with only athymic mice and TNP-Ficoll.

* Geometric mean. Standard error in parentheses.
‡ nu/+ or +/+ littermates of nu/nu mice.

to congenitally athymic (nu/nu) mice or their phenotypically normal (nu/+ and +/+ ) littermates, and immunizing them with 0.2 ml of 10% TNP-SRBC or 100 μg of TNP-Ficoll 24 h later. As expected, the phenotypically normal mice generated strong IgM and IgG anti-TNP antibody responses to both TNP-SRBC and TNP-Ficoll. These IgM responses were enhanced slightly, whereas these IgG responses were
enhanced considerably by 4.22aM8 (Table III). Also as expected, nu/nu mice made no detectable anti-TNP antibody in response to TNP-SRBC, but did produce IgM and IgG anti-TNP antibodies when immunized with TNP-Ficoll, the titer of which, in fact, exceeded that produced by their normal littermates. However, in this, as in a subsequent experiment (Table III, experiment 2), no enhancement by 4.22aM8 was seen. These findings indicate that directly or indirectly, T cells play a role in anti-IgD enhancement of in vivo humoral responses.

Effect of 4.22aM8 on Serum Immunoglobulin Levels and Spleen Cell Proliferation. To determine if the enhanced antibody responses induced by 4.22aM8 were accompanied by an increase in serum immunoglobulin, two groups of six mice were each given either 200 µg of 4.22aM8 or CBPC-101 24 h before immunization with TNP-SRBC. Sera obtained 5 d after immunization were analyzed by radial immunodiffusion for IgM and IgG2a, whereas 10-d sera were analyzed for IgG1 and IgG2b. Mice injected with 4.22aM8 showed a more substantial rise in serum IgG1 levels (+79 ± 13%) than mice injected with CBPC-101 (+22 ± 10%); changes in other isotype levels were comparable for both groups. In a second experiment in which mice were given 200 µg of either 4.22aM8 or CBPC-101 without subsequent antigenic challenge, no substantial differences were seen in IgM or total IgG serum levels between the two groups. These data are consistent with our finding that 4.22aM8 does not enhance anti-TNP antibody production stimulated by low doses of TNP-SRBC (i.e., anti-δ-chain by itself has little or no activity as a polyclonal activator of antibody secretion).

Spleen cells from mice given either 4.22aM8 or CBPC-101 1, 3, 5, or 7 d before were analyzed for their ability to incorporate [3H]thymidine during 4- and 24-h in vitro incubations. 4.22aM8 had no effect on spleen cell [3H]thymidine incorporation 1, 3, and 5 d after injection and a twofold stimulatory effect 7 d after injection. In a second experiment, even this slight stimulatory effect at day 7 was not seen.

As another measure of the effect of 4.22aM8 on spleen cell proliferation, splenic fragments from mice given 4.22aM8 or CBPC-101 3 or 7 d before killing were fixed, sectioned, stained with hematoxalin and eosin, and examined microscopically for mitotic figures. Less than 1% of splenic lymphoid follicle cells from either 4.22aM8- or CBPC-101-treated mice showed mitotic figures.

Discussion

The intravenous administration of anti-δ-chain antibody removes almost all sIgD from mouse splenic B lymphocytes but leaves most sIgM on the majority of these cells intact. When antigen is given simultaneously, or 1 day after, anti-δ-chain antibody, a marked enhancement of antigen-specific IgG responses and a smaller increase in IgM responses are observed. This enhancement occurs in the absence of detectable anti-δ-chain-stimulated polyclonal splenic B cell proliferation or terminal differentiation. These data are similar to previous studies of the effects of anti-δ-chain on specific antibody responses in the rhesus monkey and rat (10–12, 23, 24). Our results differ, however, from experiments by Dresser and Parkhouse (25), which suggested that anti-mouse δ-chain antisera inhibit the response to simultaneously, or subsequently, injected antigens. These experiments were unlike ours in that anti-SRBC rather than anti-TNP antibody responses were examined, a conventional rabbit anti-mouse δ-chain antiserum was used instead of a monoclonal mouse anti-mouse δ-chain antibody, and splenic plaque-forming cells rather than serum antibody levels were measured. In
preliminary experiments, our affinity-purified RaMδ antibody enhances IgG responses as well as or better than 4.22aMδ and does not suppress anti-TNP responses at doses varying from 5 μg to 2 mg. In addition, both 4.22aMδ and RaMδ can enhance the IgG anti-SRBC response of mice immunized with TNP-SRBC 1 d after treatment. Furthermore, the numbers of direct and indirect anti-SRBC plaque-forming cells are substantially enhanced by simultaneous administration of anti-δ-chain antibody with SRBC (26).

In addition to establishing that anti-δ-chain antibody has an adjuvant effect on specific antibody production to TNP-Ficoll and TNP-SRBC, our data indicate that this adjuvant effect is not observed when suboptimal, but immunogenic, antigen doses are used. Furthermore, this adjuvant effect is observable in nu/+ but not nu/nu mice and, hence, appears to be T cell dependent. The T cell dependence of anti-δ-chain antibody enhancement of the TNP-Ficoll response is somewhat surprising, as this antigen is widely thought to be T independent and elicits a strong humoral immune response in nu/nu mice (27). However, recent studies by Kettman and Dodd (28) and Mond et al. (29) indicate that T cell help is required for an optimal in vitro antibody response to TNP-Ficoll by B cells from normal mice.

To be consistent with our data, models of anti-δ-chain antibody enhancement should account for: (a) the requirement for T cell help, (b) the requirement for a relatively high antigen dose, and (c) the wide range of anti-δ-chain antibody concentrations that produce enhancement. We feel that these observations can best be explained within the confines of the two-signal theory of B cell stimulation; that is, that B lymphocytes are optimally stimulated to differentiate into antibody-secreting cells by the triggering of both slg receptors and other receptors specific for T helper substances and/or polyclonal activators (30). Anti-δ-chain antibody could have an adjuvant effect on antigen-induced B lymphocyte terminal differentiation by increasing the amount or effect of T cell help on B cells, by interfering with T cell suppression or T cell dependent anti-idiotypic suppression of B cells, or by changing the quantity and quality of the binding of ligand to B cell slg. These proposed effects of anti-δ-chain antibody upon a humoral immune response are not mutually exclusive, but, for convenience, can be expressed as three separate models. The first model proposes that T cells would respond to 4.22aMδ by generating helper factors specific for 4.22aMδ which would be focused onto B cells polyclonally by binding to 4.22aMδ that is associated with slgD. However, our failure to detect 4.22aMδ associated with spleen cells by sensitive immunofluorescence techniques decreases the likelihood of this hypothesis.

A second model notes that anti-TNP antibody responses are limited by antibodies or suppressor substances specific for idiotypic determinants on anti-TNP antibodies (24). Because the binding of these idiotypic-specific substances to B cell slg is required, presumably, for their suppressive effects, the loss of slgD might interfere with their binding and, thus, enhance antigen-specific antibody responses. However, this model requires that slgM, which is still present in large amounts on most B cells after the 4.22aMδ injection, is not able to bind idiotypic-specific suppressor substances and/or is not able to transmit a suppressive signal to the same degree as slgD or as slgM together with slgD.

A third model proposes that the binding of anti-δ-chain antibody (or antigen) to slgD partially activates B lymphocytes. This partial activation would be insufficient
to induce terminal differentiation, but might make the B cell respond more readily to T cell helper factors or other stimulators of B cell terminal differentiation. Several lines of evidence suggest that anti-δ-chain antibody may partially activate B lymphocytes. First, although 4.22aMδ does not induce B lymphocyte proliferation in vitro, both affinity-purified RaMδ and goat anti-mouse δ-chain antibody cause in vitro B lymphocyte proliferation (31). Second, treatment of murine B lymphocytes in vivo or in vitro with monoclonal or affinity purified anti-δ-chain antibody causes these cells to express considerably more I-region associated (Ia) determinants on their cell surfaces as detected by immunofluorescence using a FACS (32). This phenomenon is of particular interest because Ia appears to play a role in the interaction of B cells, T cells, and macrophages and could be a receptor for T helper factors (33, 34). Third, Parker et al. have found that 4.22aMδ (or RaMδ) bound to polyacrylamide beads greatly enhances concanavalin A helper-factor-induced in vitro differentiation of murine B lymphocytes into Ig-secreting cells ([35]; and D. Parker. Personal communication.).

The concept that anti-δ-chain antibody partially activates B lymphocytes fits well with the observation that 4.22aMδ enhancement of humoral immune responses requires the presence of both T lymphocytes and considerable doses of antigen. Both antigen and T lymphocytes would be necessary for the generation of carrier- and/or idiootype-specific T helper factors that are required to induce terminal differentiation of the partially activated B lymphocytes. The lack of 4.22aMδ enhancement of the antibody response to suboptimal antigen doses leads us to hypothesize that fairly high levels of T help are required to produce this enhancement and that such amounts of T help are produced only when high quantities of antigen are used. Alternatively, large antigen doses may be required for optimal focusing of antigen-specific helper factors onto B cells that have lost slgD (i.e., helper factors may bind to antigen that has itself bound to B lymphocyte surface Ig, or antigen may itself be incorporated into helper factor). Reports that some anti-δ-chain antibodies block the in vitro antibody response to TNP-Ficol and SRBC (36, 37) might raise the possibility that T cell help is limiting in these in vitro systems, and suggest that, under these circumstances, partial activation of B lymphocytes by anti-δ-chain antibody might actually suppress terminal differentiation. According to this concept, anti-δ-chain antibody mimics the effect of large antigen doses, which can suppress B cell terminal differentiation in the absence of T help but stimulate antibody secretion when sufficient T help is present (12, 37, 38).

If anti-δ-chain antibody enhances antigen-specific antigen responses by partially activating B lymphocytes, as suggested by our third model, it can be questioned why partial activation is not achieved to the same extent by antigen alone as by the combination of antigen and anti-δ-chain antibody, because both bind to slgD. One possibility is that the combination of anti-δ-chain antibody plus antigen might enhance the partial activation of B cells induced by antigen alone simply by increasing the quantity of ligand bound to B cell slg. However, the observation that 25 μg of 4.22aMδ enhances the IgG anti-TNP response to a large dose of TNP-SRBC as well as 800 μg of this antibody does not support this hypothesis, because more slgD will be bound by 800 μg of anti-δ-chain antibody than by 25 μg.

A second possibility is that anti-δ-chain antibody enhances the B cell partial activation produced by antigen alone by increasing the ratio of slgD:slgM bound by
ligand. We find this hypothesis attractive as it is consistent with observations that the binding of ligand to sIgM is more tolerogenic to a cell than the binding of the same ligand to sIgD (39–41).

Summary

Heterologous anti-δ-chain antibodies have an adjuvant effect on specific in vivo humoral immune responses to simultaneously, or subsequently, injected antigens in the rat and rhesus monkey. We have used a hybridoma-secreted antibody that binds murine δ-chain of the a allotype (4.22αMΔa) to study this phenomenon in the mouse and to investigate the mechanism of this effect. Injection of 4.22αMΔa into BALB/c mice removes almost all surface IgD (sIgD) from splenic B lymphocytes. sIgD does not reappear until the serum level of 4.22αMΔa decreases 5–7 d after injection. 4.22αMΔa fails to induce detectable proliferation or to raise total serum Ig levels substantially above control values. However, 4.22αMΔa injected 24 h before antigen elicits an approximately twofold enhancement of serum IgM and a 3- to 10-fold enhancement of serum IgG anti-trinitrophenyl (TNP) antibodies in response to immunization with optimal doses of TNP-Ficoll or TNP-sheep red blood cells (TNP-SRBC). 4.22αMΔa injected 1 wk before or 3 d after TNP-SRBC, however, has no effect on IgG anti-TNP levels. The adjuvant effect of anti-δ-chain antibody was markedly decreased when suboptimal antigen doses were used. Furthermore, even in the case of TNP-Ficoll, a relatively T-independent antigen, the ability of 4.22αMΔa to enhance the anti-TNP antibody response was T cell dependent. Our data suggest that the binding of anti-δ-chain antibody to cell sIgD may partially activate B lymphocytes and make them more capable of differentiating into antibody-secreting cells when stimulated by antigen-specific T cell help.

We thank Ms. Luba Trost for her expert technical assistance, Dr. Michael Potter for his gift of murine plasmacytoma proteins, and Doctors Eleanor Metcalf, William Paul, and Ellen Vitetta for their helpful discussions and advice.

Received for publication 6 February 1980 and in revised form 28 April 1980.

References

1. Rowe, D. S., and J. L. Fahey. 1965. A new class of human immunoglobulins. II. Normal serum IgD. J. Exp. Med. 121:185.
2. van Boxel, J. A., W. E. Paul, W. D. Terry, and I. Green. 1972. IgD bearing human lymphocytes. J. Immunol. 109:6448.
3. Rowe, D. S., K. Hug, L. Forni, and B. Pernis. 1973. Immunoglobulin D as a lymphocyte receptor. J. Exp. Med. 138:965.
4. Knapp, W., R. L. H. Bolhuis, J. Radi, and W. Hijmans. 1973. Independent movement of IgD and IgM molecules on surface of individual lymphocytes. J. Immunol. 111:1295.
5. Martin, L. N., G. A. Leslie, and R. Hindes. 1976. Lymphocyte surface IgD and IgM in non-human primates. Int. Arch. Allergy Appl. Immunol. 51:320.
6. Melcher, U., E. S. Vitetta, M. McWilliams, M. E. Lamm, J. M. Phillips-Quagliata, and J. W. Uhr. 1974. Cell surface immunoglobulin. X. Identification of an IgD-like molecule on the surface of murine splenocytes. J. Exp. Med. 140:1427.
7. Abney, E. R., and R. M. E. Parkhouse. 1974. Candidate for immunoglobulin D present on murine B lymphocytes. Nature (Lond.). 252:600.
8. Ruddick, J. H., and G. A. Leslie. 1977. Structure and biological function of human IgD. XI. Identification and ontogeny of a rat lymphocyte immunoglobulin having antigenic cross-reactivity with human IgD. J. Immunol. 118:1025.

9. Bazin, H., A. Beckers, G. Urbain-Vansanten, R. Pauwels, C. Bruyns, A. F. Tilkin, B. Plateau, and J. Urbain. 1978. Transplantable IgD immunoglobulin-secreting tumors in rat. J. Immunol. 121:2077.

10. Pernis, B. 1977. Lymphocyte membrane IgD. Immunol. Rev. 37:210.

11. Martin, L. N., and G. A. Leslie. 1979. In vivo effects of antisera to IgD on surface immunoglobulins, serum immunoglobulins and lymphocyte blastogenesis in rhesus monkeys. Immunology. 37:253.

12. Finkelman, F. D., and P. E. Lipsky. 1979. The role of cell membrane immunoglobulin in primate B lymphocyte differentiation. Immunol. Rev. 45:117.

13. Pearson, T., G. Galfre, A. Ziegler, and C. Milstein. 1977. A myeloma hybrid producing antibody specific for an allotypic determinant on “IgD-like” molecules of the mouse. Eur. J. Immunol. 7:684.

14. Oi, V. T., P. P. Jones, J. W. Goding, L. A. Herzenberg, and L. A. Herzenberg. 1978. Properties of monoclonal antibodies to mouse Ig allotypes, H-2, and Ia antigens. Curr. Top. Microbiol. Immunol. 81:115.

15. Kessler, S. W., V. L. Woods, F. D. Finkelman, and I. Scher. 1979. Membrane orientation and location of multiple and distinct allotypic determinants of mouse membrane IgD. J. Immunol. 123:2772.

16. Rittenberg, M. B., and C. Pratt. 1969. Anti-trinitrophenyl (TNP) plaque assay. Primary response of BALB/c mice to soluble and particulate immunogen. Proc. Exp. Biol. Med. 132:575.

17. Hunter, K. W., Jr., F. D. Finkelman, G. T. Strickland, P. T. Sayles, and I. Scher. 1979. Defective resistance to Plasmodium yoelii in CBA/N mice. J. Immunol. 123:133.

18. Finkelman, F. D., and P. E. Lipsky. 1978. Immunoglobulin secretion by human splenic lymphocytes in vitro: the effects of antibodies to IgM and IgD. J. Immunol. 120:1465.

19. Hunter, W. M., and F. C. Greenwood. 1962. Preparation of iodine-131 labeled human growth hormone of high specific activity. Nature (Lond.). 194:495.

20. Finkelman, F. D., and I. Scher. 1979. Rhesus monkey B lymphocyte surface immunoglobulin: analysis with a fluorescence activated cell sorter. J. Immunol. 122:1757.

21. Finkelman, F. D., V. Woods, A. Berning, and I. Scher. 1979. Demonstration of mouse serum IgD. J. Immunol. 123:1253.

22. Voller, A., D. E. Bidwell, A. Bartlett, and R. Edwards. 1977. A comparison of isotopic and enzyme-immunoassays for tropical parasitic diseases. Trans. R. Soc. Trop. Med. Hyg. 71:431.

23. Cuchens, M. A., L. N. Martin, and G. A. Leslie. 1978. The effects of anti-IgD on serum immunoglobulins antibody production and immunoglobulin-bearing cells in adult rats. J. Immunol. 121:2257.

24. Schrater, A. F., E. A. Goidl, G. J. Thorbecke, and G. W. Siskind. 1979. Production of auto-anti-idiotypic antibody during the normal immune response to TNP-Ficol. I. Occurrence in AKR/J and BALB/c mice of hapten-augmentable, anti-TNP plaque-forming cells and their accelerated appearance in recipients of immune spleen cells. J. Exp. Med. 150:138.

25. Dresser, D. W., and R. M. E. Parkhouse. 1978. The effect of the parenteral administration of a rabbit anti-(mouse)-IgD serum on the immune response of mice to sheep erythrocytes. Immunology. 35:1027.

26. Finkelman, F. D., J. J. Mond, V. L. Woods, S. B. Wilburn, A. Berning, E. Sehgal, and I. Scher. 1980. Effects of anti-immunoglobulin antibodies on murine B lymphocytes and humoral immune responses. Immunol. Rev. 52:38.

27. Sharon, R., P. R. B. McMaster, A. M. Kask, J. D. Owens, and W. E. Paul. 1975. DNP-lys-
506 ANTI-δ-CHAIN-ANTIBODY-ENHANCED MURINE ANTIBODY SECRETION

Ficoll: a T-independent antigen which elicits both IgM and IgG anti-DNP antibody-secreting cells. *J. Immunol.* 32:327.

28. Kettman, J. R., and K. Dodd. Requirement for T cells for optimal *in vitro* responses to TNP-lys-Ficoll. *Cell. Immunol.* In press.

29. Mond, J. J., P. K. A. Mongini, D. Sieckmann, and W. E. Paul. 1979. Role of T lymphocytes in the response to TNP-AECM-Ficoll. *J. Immunol.* In press.

30. Cohn, M., and B. Blomberg. 1975. The self-non-self discrimination: a one or two signal mechanism. *Scand. J. Immunol.* 4:1.

31. Seickmann, D., F. Finkelman, and I. Scher. 1980. Induction of DNA synthesis by heterologous anti-δ in mouse spleen cell cultures. *Fed. Proc.* 39:806.

32. Mond, J. J., E. Sehgal, and F. D. Finkelman. 1980. Increased density of I-region associated (Ia) antigens on B cells stimulated with anti-IgD antibodies. *Fed. Proc.* 39:806.

33. Pierce, S. K., and N. R. Klinman. 1975. The allogeneic restriction of carrier-specific enhancement of monoclonal B-cell responses. *J. Exp. Med.* 142:1165.

34. Benacerraf, B., and R. N. Germain. 1978. The immune response genes of the major histocompatibility complex. *Immunol. Rev.* 38:70.

35. Parker, D. C., J. J. Fothergill, and D. C. Wadsworth. 1979. B lymphocyte activation by insoluble anti-immunoglobulin: induction of immunoglobulin by a T cell-dependent soluble factor. *J. Immunol.* 123:931.

36. Cambier, J. C., F. S. Ligler, J. W. Uhr, J. R. Kettman, and E. S. Vitetta. 1978. Blocking of primary *in vitro* antibody responses to thymus-independent antigens with antiserum specific for IgM or IgD. *Proc. Natl. Acad. Sci. U. S. A.* 75:432.

37. Zitron, I. M., D. E. Mosier, and W. E. Paul. 1977. The role of surface IgD in the response to thymic-independent antigens. *J. Exp. Med.* 146:1707.

38. Metcalf, E. S., and N. Klinman. 1976. In vitro tolerance induction of neonatal murine B cells. *J. Exp. Med.* 143:1327.

39. Dosch, H., S. Kwong, F. Tsui, B. Zimmerman, and E. W. Gelfand. 1979. Role of surface IgM and IgD in the functional differentiation of human B lymphocytes: effect of papain treatment. *J. Immunol.* 123:557.

40. Vitetta, E. S., J. C. Cambier, F. S. Ligler, J. R. Kettman, and J. W. Uhr. 1977. B-cell tolerance. IV. Differential role of surface IgM and IgD in determining tolerance susceptibility of murine B cells. *J. Exp. Med.* 146:1804.

41. Scott, D. W., J. E. Layton, and G. J. V. Nossal. 1977. Role of IgD in the immune response and tolerance. I. Anti-δ pretreatment facilitates tolerance induction in adult B cells in vitro. *J. Exp. Med.* 146:1473.

42. Cambier, J. C., E. S. Vitetta, J. R. Kettman, G. Wetzel, and J. W. Uhr. 1977. B cell tolerance. III. Effects of papain-mediated cleavage of cell surface IgD on tolerance susceptibility of murine B cells. *J. Exp. Med.* 146:107.